Thursday, April 4, 2013
This week in therapeutics
Publication and contact
Dipeptidyl peptidase-4 (DPP-4;
Cell culture studies
identified DDP-4 as the receptor of human coronavirus-Erasmus Medical Center
(hCoV-EMC) and suggest that blocking the protein could help treat infection.
In cell culture, hCoV-EMC bound and infected cells that expressed DDP-4 but
not cells that lacked the protein. In cells expressing DDP-4, polyclonal
DPP-4 antiserum blocked hCoV-EMC infection. However, in cell culture,
hCoV-EMC infection could not be blocked with the DPP-4 inhibitors Glactiv
suggesting binding takes place outside of the enzyme's catalytic region. Next
steps include generating humanized mAbs that block the interaction between
hCoV-EMC and DPP-4.
& Co. Inc. and Ono
Pharmaceutical Co. Ltd. market Glactiv sitagliptin to treat
AG markets Equa vildagliptin to treat diabetes.
Squibb Co., AstraZeneca
plc and Otsuka
Pharmaceutical Co. Ltd. market Onglyza saxagliptin to treat
Published online April 4, 2013
Patent application filed;
Raj, V.S. et al. Nature;
published online March 13, 2013;
Contact: Bart L. Haagmans, Erasmus Medical Center, Rotterdam,
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]